Where does Gilead Sciences, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Gilead Sciences, Inc. ranks #817 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Gilead Sciences, Inc. hold?

Gilead Sciences, Inc. holds 561 US utility patents granted between 2015 and 2025, spanning 18 technology areas.

What is Gilead Sciences, Inc.'s Innovation Score?

Gilead Sciences, Inc. has an Innovation Score of 57.4 out of 100 (top 5% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Gilead Sciences, Inc.'s patent grant rate increasing or decreasing?

Gilead Sciences, Inc.'s recent grant velocity is -2% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Gilead Sciences, Inc.'s patents?

Gilead Sciences, Inc.'s patents average 19.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Gilead Sciences, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Gilead Sciences, Inc.

Q: What technology areas does Gilead Sciences, Inc. focus on?

Gilead Sciences, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 492 patents. Grants appear in 18 CPC subclasses total.

USPTO PatentsView assignee record - 561 granted patents across 18 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Gilead ranks #817 of 49,997 tracked US assignees by granted-patent volume, with 561 patents across 18 technology areas.

#817
of 49,997 US assignees by volume: Top 5%
by Innovation Score (57.4/100): 19.1
avg claims per patent: -2%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R817 · US Corporation #817 · 561 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-FLAT · BOOK-FULL

GRANTS-MID 561 grants
TOP-DECILE #817/49,997
PHOTO-FINISH Arts
CPC-FOCUS A61P · 18 areas
INNOV-PAR 57.4/100
CLAIMS-RICH 19.1 claims/avg
TYPE-USCORP US Corporation
VEL-FLAT -2% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Electronic Arts Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Research Foundation… · near

57
UNIVERSITÉ DE Bordeaux · near

57
UNIVERSITÉ DE Lille · near

57
University of Hong… · near

57
Gilead Sciences · this assignee

57
3D Lighting… · lowest

7

What this shows Gilead's Innovation Score is 57.4/100 (top 5% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Gilead's grants concentrate

Gilead Sciences, Inc. is a focused PatentsView assignee: 18 CPC subclasses with 87.7% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2024 (74 grants) versus a trough of 37 in 2020. By volume, Gilead sits between Sekisui Chemical Co., Ltd. and Valeo Vision.

Gilead's three-year grant acceleration

From 2019–2021 to 2022–2024, Gilead Sciences, Inc. moved from 133 to 181 grants (1.36x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #562. See the growth leaderboard.

Sekisui Chemical

565
Polaris Industries

563
Under Armour

563
Arts

561
Yaskawa Denki

561
Gilead Sciences ◀

561
Toto

560
Unicharm

560
Valeo Vision

559

What this shows Gilead holds 561 patents at rank #817, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Gilead

By rank, the assignees closest to #817 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Gilead's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Gilead, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (57 here).

UNIVERSITÉ DE Bordeaux 57 University of Hong Kong 57 Research Foundation OF THE City University OF NEW York 57 UNIVERSITÉ DE Lille 57

Similar claim depth

Nearest assignees by average claims per patent (19.1 here).

University of Washington 19.1 avg Stmicroelectronics PTE Ltd 19.1 avg Space Systems/Loral, LLC 19.1 avg Laird Technologies, Inc. 19.1 avg

Gilead's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

57 Top 5% higher than 95% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Gilead Sciences, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	54	9.6%
2016	52	9.3%
2017	56	10.0%
2018	46	8.2%
2019	55	9.8%
2020	37	6.6%
2021	41	7.3%
2022	42	7.5%
2023	65	11.6%
2024	74	13.2%
2025partial year	39	7.0%

Which technologies does Gilead Sciences, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 492

C07D - Heterocyclic Compounds 413

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 358

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 86

Y02A - Technologies FOR Adaptation TO Climate Change 72

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 56

C07C - Acyclic OR Carbocyclic Compounds 54

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 53

C07K - Peptides 52

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 12

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 12

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 10

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 4

C12Y - Enzymes 4

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 3

Top 15 of 18 technology areas

Where it ranks

Overall rank by patents

#817

of 49,997 tracked assignees

Innovation Score

57.4 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Gilead Sciences, Inc.'s patent record in context - here's where to go next.

Gilead Sciences, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 87.7% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #817 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Gilead Sciences, Inc. against Sekisui Chemical Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 57.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.